Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirion Therapeutics has entered into an exclusive licensing agreement with Bridge Pharma for the worldwide rights to develop and market topical ophthalmic formulations containing Bridge Pharma's proprietary anti- inflammatory agent norketotifen.
Subscribe to our email newsletter
Under the terms of this licensing agreement, Sirion will have the rights to manufacture, sell and distribute norketotifen for ocular use either alone or in combination with other drugs.
Roger Vogel, chief medical officer of Sirion, said: “This agreement represents yet another significant milestone for Sirion. We are very excited about the medical and market potential of the norketotifen molecule.”